Selected research
Industry Research
Leiomyosarcoma Drug Industry Research Report 2026
Market perspective
The global Leiomyosarcoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Leiomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Leiomyosarcoma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Leiomyosarcoma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Leiomyosarcoma Drug include Novartis AG, Merck & Co., Inc., Vicore Pharma AB, Mirati Therapeutics Inc., Karyopharm Therapeutics, Inc., Cell Medica Limited, BeiGene, Ltd. and Advenchen Laboratories, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Leiomyosarcoma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Leiomyosarcoma Drug Market by Company
Novartis AG
Merck & Co., Inc.
Vicore Pharma AB
Mirati Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Cell Medica Limited
BeiGene, Ltd.
Advenchen Laboratories, LLC
Leiomyosarcoma Drug Segment by Type
BGB-290
C-21
AL-3818
Others
Leiomyosarcoma Drug Segment by Application
Clinic
Hospital
Others
Leiomyosarcoma Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leiomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leiomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leiomyosarcoma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Leiomyosarcoma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Leiomyosarcoma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Leiomyosarcoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BGB-290
- C-21
- AL-3818
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- Vicore Pharma AB
- Mirati Therapeutics Inc.
- Karyopharm Therapeutics, Inc.
- Cell Medica Limited
- BeiGene, Ltd.
- Advenchen Laboratories, LLC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Leiomyosarcoma Drug Market Size (2021-2032)
- 2.2.2 Global Leiomyosarcoma Drug Sales (2021-2032)
- 2.2.3 Global Leiomyosarcoma Drug Market Average Price (2021-2032)
- 2.3 Leiomyosarcoma Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 BGB-290
- 2.3.3 C-21
- 2.3.4 AL-3818
- 2.3.5 Others
- 2.4 Leiomyosarcoma Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Leiomyosarcoma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Leiomyosarcoma Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Leiomyosarcoma Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Leiomyosarcoma Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Leiomyosarcoma Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Leiomyosarcoma Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Leiomyosarcoma Drug, Product Type & Application
- 3.8 Global Manufacturers of Leiomyosarcoma Drug, Established Date
- 3.9 Global Leiomyosarcoma Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Leiomyosarcoma Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Vicore Pharma AB
- 4.3.1 Vicore Pharma AB Company Information
- 4.3.2 Vicore Pharma AB Business Overview
- 4.3.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio
- 4.3.5 Vicore Pharma AB Recent Developments
- 4.4 Mirati Therapeutics Inc.
- 4.4.1 Mirati Therapeutics Inc. Company Information
- 4.4.2 Mirati Therapeutics Inc. Business Overview
- 4.4.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio
- 4.4.5 Mirati Therapeutics Inc. Recent Developments
- 4.5 Karyopharm Therapeutics, Inc.
- 4.5.1 Karyopharm Therapeutics, Inc. Company Information
- 4.5.2 Karyopharm Therapeutics, Inc. Business Overview
- 4.5.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio
- 4.5.5 Karyopharm Therapeutics, Inc. Recent Developments
- 4.6 Cell Medica Limited
- 4.6.1 Cell Medica Limited Company Information
- 4.6.2 Cell Medica Limited Business Overview
- 4.6.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cell Medica Limited Leiomyosarcoma Drug Product Portfolio
- 4.6.5 Cell Medica Limited Recent Developments
- 4.7 BeiGene, Ltd.
- 4.7.1 BeiGene, Ltd. Company Information
- 4.7.2 BeiGene, Ltd. Business Overview
- 4.7.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio
- 4.7.5 BeiGene, Ltd. Recent Developments
- 4.8 Advenchen Laboratories, LLC
- 4.8.1 Advenchen Laboratories, LLC Company Information
- 4.8.2 Advenchen Laboratories, LLC Business Overview
- 4.8.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio
- 4.8.5 Advenchen Laboratories, LLC Recent Developments
5 Global Leiomyosarcoma Drug Market Scenario by Region
- 5.1 Global Leiomyosarcoma Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Leiomyosarcoma Drug Sales by Region: 2021-2032
- 5.2.1 Global Leiomyosarcoma Drug Sales by Region: 2021-2026
- 5.2.2 Global Leiomyosarcoma Drug Sales by Region: 2027-2032
- 5.3 Global Leiomyosarcoma Drug Revenue by Region: 2021-2032
- 5.3.1 Global Leiomyosarcoma Drug Revenue by Region: 2021-2026
- 5.3.2 Global Leiomyosarcoma Drug Revenue by Region: 2027-2032
- 5.4 North America Leiomyosarcoma Drug Market Facts & Figures by Country
- 5.4.1 North America Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Leiomyosarcoma Drug Sales by Country (2021-2032)
- 5.4.3 North America Leiomyosarcoma Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Leiomyosarcoma Drug Market Facts & Figures by Country
- 5.5.1 Europe Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Leiomyosarcoma Drug Sales by Country (2021-2032)
- 5.5.3 Europe Leiomyosarcoma Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Leiomyosarcoma Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Leiomyosarcoma Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Leiomyosarcoma Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Leiomyosarcoma Drug Market Facts & Figures by Country
- 5.7.1 South America Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Leiomyosarcoma Drug Sales by Country (2021-2032)
- 5.7.3 South America Leiomyosarcoma Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Leiomyosarcoma Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Leiomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Leiomyosarcoma Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Leiomyosarcoma Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Leiomyosarcoma Drug Sales by Type (2021-2032)
- 6.1.1 Global Leiomyosarcoma Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Leiomyosarcoma Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Leiomyosarcoma Drug Revenue by Type (2021-2032)
- 6.2.1 Global Leiomyosarcoma Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Leiomyosarcoma Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Leiomyosarcoma Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Leiomyosarcoma Drug Sales by Application (2021-2032)
- 7.1.1 Global Leiomyosarcoma Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Leiomyosarcoma Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Leiomyosarcoma Drug Revenue by Application (2021-2032)
- 7.2.1 Global Leiomyosarcoma Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Leiomyosarcoma Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Leiomyosarcoma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Leiomyosarcoma Drug Value Chain Analysis
- 8.1.1 Leiomyosarcoma Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Leiomyosarcoma Drug Production Mode & Process
- 8.2 Leiomyosarcoma Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Leiomyosarcoma Drug Distributors
- 8.2.3 Leiomyosarcoma Drug Customers
9 Global Leiomyosarcoma Drug Analyzing Market Dynamics
- 9.1 Leiomyosarcoma Drug Industry Trends
- 9.2 Leiomyosarcoma Drug Industry Drivers
- 9.3 Leiomyosarcoma Drug Industry Opportunities and Challenges
- 9.4 Leiomyosarcoma Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst